mynth
10/2022MajorityLBO

Cbpe Capital takes majority stake in Veincentre

UNITED KINGDOM Health Providers / Outpatient Care / Aesthetic & Cosmetic Clinics REV 1m GBP - 100m GBP

Context

CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics. The deal was structured to support the current management team, led by CEO Maurice McLoughlin, in the next phase of their national expansion strategy. The rationale for the acquisition is rooted in the high demand for specialized outpatient vascular services in the UK and Veincentre,s proven, scalable clinical model. CBPE intends to leverage its extensive experience in multi-site healthcare to further increase the group's clinic density across the UK. The operation was supported by a debt advisory from FRP Advisory and commercial due diligence from Candesic.

Veincentre, which reported an EBITDA margin of [members only] in 2022, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Veincentre is the United Kingdom,s leading specialist provider of minimally invasive treatments for venous insufficiency, primarily focusing on the treatment of varicose veins and venous ulcers. The company operates a high-efficiency business model centered on outpatient procedures performed under local anesthetic, allowing patients to undergo complex vascular treatments with rapid recovery times. Its value proposition is built on clinical excellence, utilizing a dedicated team of consultant vascular surgeons and interventional radiologists to provide specialized care across a growing national network of clinics. Veincentre,s strategy focuses on increasing patient access to high-quality vascular services that are often underserved by traditional healthcare systems. By concentrating exclusively on venous reflux disorders, the group achieves significant operational expertise and high patient satisfaction ratings. The company serves a large addressable market, as venous conditions affect millions of people in the UK, and it continues to expand its geographic footprint to maintain its position as the premier dedicated venous clinical group in the country.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (GBP)

Year
Rev
EBITDA
EBIT
2022
£1–100M
£5–25M
[members only]
2021
£1–100M
£5–25M
[members only]

Other operations with Cbpe Capital

Other operations with Cbpe Capital
DateAcquirerTargetCountrySector
09/2013CBPE CAPITALCÔTE RESTAURANTSUNITED KINGDOMRestaurants / Chains

Similar deals in Health Providers

Similar deals in Health Providers
DateAcquirerTargetCountrySector
06/2023LEVINE LEICHTMAN CAPITAL PARTNERSSEV LASERUNITED STATESAesthetic & Cosmetic Clinics
11/2022RADNETHEART & LUNG IMAGINGUNITED KINGDOMRadiology
09/2022ORADIANSEREVELFRANCERadiology
09/2022EURAZEOIMAPOLEFRANCERadiology
08/2022FREEMAN SPOGLIEVERVET PARTNERSUNITED STATESVet Clinics
07/2022ANDERA PARTNERSGROUPE RESONANCE IMAGERIEFRANCERadiology
07/2022LATOUR CAPITALPHARMACIE LAFAYETTE - GROUPE HYGIE31FRANCEPharmacy
07/2022INFRAVIA CAPITALUNIVETFRANCEVet Clinics
06/2022EURAZEOSEVETYSFRANCEVet Clinics
06/2022TRITON PARTNERSESPERI CAREFINLANDNursing Homes

REFERENCES

Revenue range: REV 1m GBP - 100m GBP

EBITDA range: £5–25M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Veincentre by Cbpe Capital are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: veincentre

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Veincentre, a British company specialised in Outpatient Care, by Cbpe Capital in 2022, structured as a leveraged buyout (LBO).

What was Veincentre’s EBITDA at the time of the deal?

At the time of the transaction, Veincentre’s EBITDA was estimated within the £5–25M bracket (FY 2022). Detailed financial figures are available to members.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.